{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:28:12Z","timestamp":1762957692905,"version":"3.45.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA273542","P30CA093373"],"award-info":[{"award-number":["K08 CA273542","P30CA093373"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.euf.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T19:09:58Z","timestamp":1748632198000},"page":"411-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Shuchi","family":"Gulati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Primo N.","family":"Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.05.014_b0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euf.2025.05.014_b0010","unstructured":"SEER. Cancer of the kidney and renal pelvis - cancer stat facts. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"key":"10.1016\/j.euf.2025.05.014_b0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0020","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.05.014_b0030","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0035","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0040","doi-asserted-by":"crossref","first-page":"356.e19","DOI":"10.1016\/j.urolonc.2019.01.016","article-title":"Economic burden of renal cell carcinoma among older adults in the targeted therapy era","volume":"37","author":"Kale","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0045","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non\u2013small cell lung cancer: do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0050","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1200\/JCO.20.00136","article-title":"Is it safe to stop anti\u2013PD-1 immunotherapy in patients with metastatic melanoma who achieve a complete response?","volume":"38","author":"Davies","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0055","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1200\/JCO.20.01382","article-title":"Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors","volume":"38","author":"Piccart","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0060","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0065","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0070","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0075","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","article-title":"Assessment of nivolumab benefit\u2013risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors","volume":"28","author":"Zhao","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40425-017-0242-5","article-title":"Evaluation of dosing strategy for pembrolizumab for oncology indications","volume":"5","author":"Freshwater","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2019.02.016","article-title":"Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: what is the economic impact?","volume":"113","author":"Bayle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0090","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2019.10.015","article-title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","volume":"31","author":"Zhao","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0095","unstructured":"Office of Clinical Pharmacology. https:\/\/www.fda.gov\/media\/129248\/download."},{"key":"10.1016\/j.euf.2025.05.014_b0100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0105","unstructured":"FDA. Center for Drug Evaluation and Research. FDA approves new dosing regimen for pembrolizumab. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-dosing-regimen-pembrolizumab."},{"key":"10.1016\/j.euf.2025.05.014_b0110","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"7_suppl","key":"10.1016\/j.euf.2025.05.014_b0115","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2019.37.7_suppl.581","article-title":"Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214","volume":"37","author":"Tannir","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euf.2025.05.014_b0120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.2023.41.6_suppl.604","article-title":"Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A)","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0125","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003473","article-title":"Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Tzeng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s40425-019-0615-z","article-title":"A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy","volume":"7","author":"Ornstein","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.107030","article-title":"REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): a multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers","volume":"124","author":"Merrick","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.euf.2025.05.014_b0140","unstructured":"U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202324lbl.pdf."},{"key":"10.1016\/j.euf.2025.05.014_b0145","unstructured":"U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208692s010lbl.pdf."},{"key":"10.1016\/j.euf.2025.05.014_b0150","unstructured":"U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206947s020lbl.pdf."},{"key":"10.1016\/j.euf.2025.05.014_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102062","article-title":"Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care","volume":"89","author":"Castellano","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2025.05.014_b0160","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1002\/cncr.25583","article-title":"Sunitinib rechallenge in metastatic renal cell carcinoma patients","volume":"116","author":"Zama","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2016.04.003","article-title":"Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma\u2014results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study","volume":"62","author":"Oudard","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2025.05.014_b0170","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","article-title":"A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma","volume":"35","author":"Ornstein","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","article-title":"Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial","volume":"24","author":"Brown","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0180","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2025.05.014_b0185","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"issue":"4_suppl","key":"10.1016\/j.euf.2025.05.014_b0190","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.2024.42.4_suppl.478","article-title":"Initial screening efforts for the OPTIC RCC trial","volume":"42","author":"Haake","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41467-020-20162-8","article-title":"Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2025.05.014_b0200","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oncolo\/oyae180","article-title":"Association of circulating tumor DNA with patient prognosis in surgically resected renal cell carcinoma","volume":"29","author":"Correa","year":"2024","journal-title":"Oncologist"},{"issue":"16_suppl","key":"10.1016\/j.euf.2025.05.014_b0205","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1200\/JCO.2022.40.16_suppl.4525","article-title":"Monitoring efficacy of neoadjuvant sunitinib in metastatic renal cell carcinoma using a personalized and tumor informed ctDNA assay","volume":"40","author":"Peterson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0210","article-title":"Ultrasensitive circulating tumor DNA pilot study distinguishes complete response and partial response with immunotherapy in patients with metastatic renal cell carcinoma","volume":"7","author":"Chehrazi-Raffle","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"6_suppl","key":"10.1016\/j.euf.2025.05.014_b0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.2023.41.6_suppl.715","article-title":"Longitudinal detection of circulating tumor DNA in patients with advanced renal cell carcinoma","volume":"41","author":"Basu","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0220","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","article-title":"Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes","volume":"26","author":"Nuzzo","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euf.2025.05.014_b0225","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1148\/rg.2021200202","article-title":"Role of imaging in renal cell carcinoma: a multidisciplinary perspective","volume":"41","author":"Abou Elkassem","year":"2021","journal-title":"RadioGraphics"},{"key":"10.1016\/j.euf.2025.05.014_b0230","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1002\/cam4.2464","article-title":"Role of medical imaging for immune checkpoint blockade therapy: from response assessment to prognosis prediction","volume":"8","author":"Wei","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.euf.2025.05.014_b0235","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","article-title":"Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy","volume":"58","author":"Stillebroer","year":"2010","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.euf.2025.05.014_b0240","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA602","article-title":"Results from phase 3 study of 89Zr-DFO-girentuximab for PET\/CT imaging of clear cell renal cell carcinoma (ZIRCON)","volume":"41","author":"Shuch","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0245","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00259-020-05165-3","article-title":"18F-PSMA-1007 PET\/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results","volume":"48","author":"Mittlmeier","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euf.2025.05.014_b0250","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.2967\/jnumed.121.262668","article-title":"Total-body PET multiparametric imaging of cancer using a voxelwise strategy of compartmental modeling","volume":"63","author":"Wang","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2025.05.014_b0255","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3390\/cancers13061348","article-title":"Radiomics in renal cell carcinoma\u2014a systematic review and meta-analysis","volume":"13","author":"M\u00fchlbauer","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.euf.2025.05.014_b0260","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1148\/radiol.11110264","article-title":"Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker","volume":"261","author":"Goh","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.euf.2025.05.014_b0265","doi-asserted-by":"crossref","first-page":"W85","DOI":"10.2214\/AJR.16.17651","article-title":"CT intensity distribution curve (histogram) analysis of patients undergoing antiangiogenic therapy for metastatic renal cell carcinoma","volume":"209","author":"Boos","year":"2017","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.euf.2025.05.014_b0270","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.014_b0275","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s10147-021-02003-w","article-title":"Metastatic clear cell renal cell carcinoma: computed tomography texture analysis as predictive biomarkers of survival in patients treated with nivolumab","volume":"26","author":"Khene","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.014_b0280","unstructured":"Directorate-General for Health and Food Safety (European Commission), EY, Open Evidence, et al. Study on health data, digital health and artificial intelligence in healthcare. Publications Office of the European Union; 2022. https:\/\/data.europa.eu\/doi\/10.2875\/702007."}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925001439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T08:33:43Z","timestamp":1762936423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925001439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2405456925001439"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.014","relation":{},"ISSN":["2405-4569"],"issn-type":[{"type":"print","value":"2405-4569"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}